



Verona Pharma

May 30, 2018

Via EDGAR Transmission

Division of Corporation Finance
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attn: Abigail Jacobs

**Re: Verona Pharma plc
Registration Statement on Form F-3
Filed May 22, 2018
Registration No. 333-225107**

Dear Ms. Jacobs:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on June 1, 2018 at 4:00 p.m. Eastern Time or as soon thereafter as practicable, or at such later time as Verona Pharma plc (the "Company") or its counsel may request via telephone call to the staff. Please contact Peter Handrinou of Latham & Watkins LLP, counsel to the Company, at (617) 948-6060, or in his absence, Nathan Ajiashvili of Latham & Watkins LLP at (212) 906-2916, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.

Sincerely yours,

Verona Pharma plc

By: /s/ Piers Morgan
Name: Piers Morgan
Title: Chief Financial Officer

cc: Jan-Anders Karlsson, Verona Pharma plc
Claire Poll, Verona Pharma plc
